Table 3.

Validity (AUC, Sensitivity, Specificity) of the lncRNAs to Discriminate Between Different Groups

	AUC	p	95% C.I	Cut Off	Sensitivity	Specificity	PPV	NPV
CRC group (n= 47) from benign group (n= 49)
Tissue.LncRNA.ASB16-AS1	0.967	<0.001*	0.928–1.0	>8.24	93.62	89.80	89.80	93.62
Plasma.LncRNA.ASB16-AS1	0.934	<0.001*	0.874–0.993	>2.93	89.36	85.71	85.71	89.36
Tissue.LncRNA.AFAP1-AS1	0.944	<0.001*	0.900–0.988	>5.06	91.49	83.67	84.31	91.11
Plasma.LncRNA.AFAP1-AS1	0.923	<0.001*	0.871–0.975	>1.99	85.11	79.59	80.0	84.78
CEA (ng/mL)	0.888	<0.001*	0.825–0.950	>12	78.72	75.51	75.5	78.7
CA19-9 (U/mL)	0.754	<0.001*	0.657–0.851	>18	63.83	65.31	63.8	65.3
CRC group (n= 47) from control (n= 50)
Tissue.LncRNA.ASB16-AS1	0.996	<0.001*	0.989–1.0	>5.57	95.74	92.0	91.84	95.83
Plasma.LncRNA.ASB16-AS1	0.974	<0.001*	0.945–1.0	>1.37	91.49	88.0	87.76	89.69
Tissue.LncRNA.AFAP1-AS1	0.984	<0.001*	0.966–1.0	>3.03	91.49	90.0	89.58	91.84
Plasma.LncRNA.AFAP1-AS1	0.965	<0.001*	0.935–0.994	>1.52	87.23	84.0	83.67	87.50
Early-stage (n= 17) from benign group (n= 49)
Tissue.LncRNA.ASB16-AS1	0.909	<0.001*	0.807–1.0	>7.36	88.24	81.63	62.50	95.24
Plasma.LncRNA.ASB16-AS1	0.888	<0.001*	0.760–1.0	>2.99	82.35	91.84	77.8	93.7
Tissue.LncRNA.AFAP1-AS1	0.900	<0.001*	0.819–0.980	>5.08	76.47	85.71	65.0	91.3
Plasma.LncRNA.AFAP1-AS1	0.842	<0.001*	0.729–0.954	>2	70.59	81.63	57.1	88.9
Early-stage (n= 17) from control (n= 50)
Tissue.LncRNA.ASB16-AS1	0.988	<0.001*	0.969–1.0	>4.81	94.12	92.0	80.0	97.9
Plasma.LncRNA.ASB16-AS1	0.949	<0.001*	0.879–1.0	>0.95	88.24	62.0	44.1	93.9
Tissue.LncRNA.AFAP1-AS1	0.973	<0.001*	0.938–1.0	>3	82.35	90.0	73.7	93.7
Plasma.LncRNA.AFAP1-AS1	0.925	<0.001*	0.861–0.989	>1.52	70.59	84.0	60.0	89.4

Note: *Statistically significant at p ≤ 0.05.

Abbreviations: AUC, area under a curve; p value, probability value; CI, confidence intervals; NPV, negative predictive value; PPV, positive predictive value.